About the forum
The purpose of RDAF is to serve as a platform to exchange ideas and define actions to raise awareness of rare diseases and to improve access to treatment and patient care in Switzerland.
RDAF brings together experts from companies developing and/or commercializing treatments, diagnostics, or providing any related service in the area of rare diseases and additional experts in the field of rare diseases.
Press release - 31 January 2017
New members join the Rare Disease Action Forum
In January 2017, Alexion Pharmaceuticals, Amicus Therapeutics and Sanofi Genzyme joined the Rare Disease Action Forum (RDAF). With this growth, the Forum now includes eight member companies that are all important contributors in the field of rare diseases. Using a multi-stakeholder approach, the RDAF aims at developing and implementing solutions to improve access to diagnosis and treatment for patients with rare diseases in Switzerland.